Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
Key claim: Nicorandil is proposed as a repurposed therapeutic to modulate ABCC9 pathways and treat hippocampal sclerosis of aging, a frequent Alzheimer’s disease mimic.
Abstract
Widespread recognition of the current and projected impact of the dementia epidemic has spurred research into novel drug discovery efforts. It is well recognized by most that Alzheimer’s disease is not the only form of dementia and that beginning to turn attention to other disease states is critically important in order to alleviate this burden on the elderly population today This proposal seeks to further progress in this area through the repurposing an existing drug therapy as a potential treatment for Hippocampal Sclerosis of Aging. This disease is seldom recognized clinically and yet is the number one Alzheimer’s disease mimic the confounds are diagnostic and treatment of subjects suffering from dementia and as of yet has no potential therapeutic interventions identified. As such, the proposed study represents a cutting-edge, data-driven, low-cost, exploration of a novel disease relevant pathway that may hold promise for global efforts targeting late life dementia which is a major health priority in America today.
Why this matters
[mechanism-plausible] The proposal brings a non-Alzheimer’s dementia pathway into the drug-repurposing landscape by targeting ABCC9 pathways in hippocampal sclerosis of aging. Although the finding is tagged as early-trial evidence, the supplied description contains no human trial results, so it supports a mechanistic rationale rather than demonstrated safety, cognitive benefit, or longevity effects.